What is Akermin?
Akermin is at the forefront of cleantech innovation, specializing in the development of advanced CO2 management solutions. Situated at BRDG Park within the Danforth Plant Science Center in St. Louis, MO, the company employs a multi-disciplined approach. Its proprietary Biocatalyst Delivery System integrates enzymes into conventional industrial processes, offering energy-efficient and green alternatives for carbon dioxide management. This technology holds potential for broad application across various industrial sectors seeking sustainable operational improvements.
How much funding has Akermin raised?
Akermin has raised a total of $12.6M across 4 funding rounds:
Unspecified
$600K
Unspecified
$6.1M
Unspecified
$4.1M
Debt
$1.8M
Unspecified (2009): $600K, investors not publicly disclosed
Unspecified (2009): $6.1M, investors not publicly disclosed
Unspecified (2010): $4.1M, investors not publicly disclosed
Debt (2013): $1.8M, investors not publicly disclosed
What's next for Akermin?
With a substantial funding history, Akermin is positioned for accelerated growth and market penetration. The recent strategic investment signals confidence in its technology and its capacity to address critical environmental challenges. Future endeavors will likely focus on scaling production, expanding its market reach, and further refining its Biocatalyst Delivery System for diverse industrial applications. This capital infusion is expected to fuel research and development, enabling Akermin to solidify its position as a leader in green CO2 management solutions.
See full Akermin company page
